Clinical Trials Browser

INDUSTRY × Docetaxel × Tumor-Agnostic × Clear all

NCT05382559 2026-03-02

A Study of ASP3082 in Adults With Advanced Solid Tumors

Phase 1 Recruiting

Neoplasm Metastasis, Neoplasms

NCT00781612 2025-12-24

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT06724042 2025-12-10

Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

Phase 1 Not yet recruiting

Neoplasm Metastasis

NCT05516914 2025-11-28

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Phase 1/2 Recruiting

Neoplasms

NCT02723955 2024-12-27

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Phase 1 Completed

829 enrolled 100 charts

Neoplasms

NCT05553808 2023-01-19

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1

Phase 2 Completed

105 enrolled 31 charts

Neoplasms

NCT05552807 2022-09-23

SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1 Unknown

Carcinoma, Squamous Cell

NCT01362374 2022-01-12

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT03811418 2019-11-26

ATTILA

Phase 3 Withdrawn

Neoplasm Metastasis

NCT03057366 2019-11-18

A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

Phase 1 Completed

8 enrolled 26 charts

Neoplasms

NCT00848718 2019-11-12

MK-2206-003

Phase 1 Completed

77 enrolled 24 charts

Neoplasms

NCT01868022 2019-08-19

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

Phase 1 Completed

65 enrolled 32 charts

Neoplasms

NCT01376310 2019-02-19

GSK1120212 Rollover Study

Phase 2 Terminated

159 enrolled 9 charts

Neoplasms

NCT01284335 2019-01-10

A Safety Study in Participants With Advanced Solid Tumors

Phase 1 Terminated

234 enrolled 23 charts

Neoplasm Metastasis

NCT01911325 2018-08-14

Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

Phase 1 Terminated

Neoplasm Metastasis

NCT01472016 2017-11-21

Study of ABT-700 in Subjects With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT01192165 2017-11-13

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Phase 1 Completed

Neoplasms

NCT02088515 2017-03-03

Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma

Phase 4 Completed

Carcinoma, Squamous Cell

NCT01665417 2017-02-08

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Phase 4 Unknown

Adenocarcinoma

NCT01837667 2017-01-24

Phase I Study of LB-100 With Docetaxel in Solid Tumors

Phase 1 Completed

Neoplasms

NCT00811993 2016-11-02

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Phase 1 Terminated

Neoplasms

NCT00487786 2016-01-18

Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

Phase 1 Completed

Neoplasms

NCT00798252 2015-07-07

Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Phase 1 Completed

Neoplasm Metastasis

NCT02171676 2014-06-24

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT02171741 2014-06-24

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT00399087 2014-02-13

Phase I Trial of Docetaxel With Perifosine

Phase 1 Completed

Neoplasms

NCT00545246 2013-10-16

A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients

Phase 1 Completed

Neoplasms

NCT01204996 2012-05-30

A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

Phase 1 Completed

Neoplasms

NCT00454649 2012-04-04

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

Phase 1 Completed

102 enrolled 48 charts

Neoplasms

NCT00125411 2012-03-26

Study of Satraplatin (JM-216) in Combination With Docetaxel

Phase 1 Terminated

Neoplasms

NCT01148615 2012-01-13

A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors

Phase 1 Completed

Neoplasms

NCT00630110 2011-08-16

Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

Phase 1/2 Completed

Neoplasms

NCT00390676 2010-12-28

A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine

Phase 1 Completed

Neoplasms

NCT00432315 2010-09-14

Docetaxel in Non Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Carcinoma, Squamous Cell

NCT00539630 2007-10-04

TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN

Phase 3 Completed

Carcinoma, Squamous Cell